PDF4PRO ⚡AMP

Modern search engine that looking for books and documents around the web

Example: barber

CLINICAL STUDY PROTOCOL - Moderna

ModernaTX, Inc. 20 Aug 2020 PROTOCOL mRNA-1273-P301, amendment 3 mRNA-1273 Confidential Page 1 CLINICAL STUDY PROTOCOL PROTOCOL Title: A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled STUDY to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older PROTOCOL Number: mRNA-1273-P301 Sponsor Name: Legal Registered Address: ModernaTX, Inc. 200 Technology Square Cambridge, MA 02139 Sponsor Contact and Medical Monitor: Tal Zaks, MD, PhD, Chief Medical Officer ModernaTX, Inc. 200 Technology Square, Cambridge, MA 02139 Telephone: 1-617-209-5906 e-mail: Regulatory Agency Identifier Number(s): IND: 19745 amendment Number: 3 Date of amendment 3: 20 Aug 2020 Date of amendment 2: 31 Jul 2020 Date of amendment 1: 26 Jun 2020 Date of Original PROTOCOL : 15 Jun 2020 CONFIDENTIAL All financial and nonfinancial support for this STUDY will be provided by ModernaTX, Inc.

Main Rationale for the Amendment: The main purpose of this amendment is to make changes to the protocol in response to feedback from CBER. The summary of changes table provided here describes the major changes made in Amendment 3 relative to Amendment 2, including the sections modified and the corresponding rationales. Minor

Loading..

Tags:

  Protocol, Relative, Amendment

Information

Domain:

Source:

Link to this page:

Please notify us if you found a problem with this document:

Spam in document Broken preview Other abuse

Transcription of CLINICAL STUDY PROTOCOL - Moderna

Related search queries